Rchr
J-GLOBAL ID：200901084252088986   Update date: Apr. 10, 2024

Nagata Noriyo

ナガタ ノリヨ | Nagata Noriyo
Affiliation and department：
National Institute of Infectious Diseases

About National Institute of Infectious Diseases


Research field  (2)： Virology ,  Experimental pathology
Research keywords  (4)： Virology ,  Pathology ,  Animal model ,  Emerging and re-emerging infection
Research theme for competitive and other funds  (13)：
  • 2019 - 2023 動物モデルを用いたエンテロウイルスD68による弛緩性麻痺発現機序の解明
  • 2020 - 2022 ウイルス感染モデルを用いた嗅覚神経系の免疫機構の解明
  • 2018 - 2021 Analysis of respiratory virus activating protease TMPRSS2 and its inhibitor compounds
  • 2015 - 2019 Development of animal models for study on persistent infection with pancreatropic and cardiotropic picornaviruses
  • 2012 - 2017 Competition between the host and virus in the target tissues
Show all
Papers (150)：
  • Takeshi Kurosu, Yusuke Sakai, Yasusi Ami, Masayuki Shimojima, Tomoki Yoshikawa, Shuetsu Fukushi, Noriyo Nagata, Tadaki Suzuki, Hideki Ebihara, Masayuki Saijo. Mice, myeloid cells, and dengue: a new model for unraveling vascular leakage mysteries. Frontiers in microbiology. 2024. 15. 1367672-1367672
  • Hikaru Fujii, Shuetsu Fukushi, Tomoki Yoshikawa, Noriyo Nagata, Satoshi Taniguchi, Masayuki Shimojima, Souichi Yamada, Hideki Tani, Akihiko Uda, Takahiro Maeki, et al. Pathological and virological findings of type I interferon receptor knockout mice upon experimental infection with Heartland virus. Virus research. 2023. 340. 199301-199301
  • Takeshi Kurosu, Daisuke Okuzaki, Yusuke Sakai, Mohamad Al Kadi, Supranee Phanthanawiboon, Yasusi Ami, Masayuki Shimojima, Tomoki Yoshikawa, Shuetsu Fukushi, Noriyo Nagata, et al. Dengue virus infection induces selective expansion of Vγ4 and Vγ6TCR γδ T cells in the small intestine and a cytokine storm driving vascular leakage in mice. PLoS neglected tropical diseases. 2023. 17. 11. e0011743
  • Mizuki Fujisawa, Yu Adachi, Taishi Onodera, Nozomi Shiwa-Sudo, Naoko Iwata-Yoshikawa, Noriyo Nagata, Tadaki Suzuki, Shinji Takeoka, Yoshimasa Takahashi. High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection. Biochemical and biophysical research communications. 2023. 673. 114-120
  • 齋藤 智也, 影山 努, 嶋田 聡, 横田 栄一, 吉見 逸郎, 海老原 秀喜, 下島 昌幸, 吉河 智城, 黒須 剛, 鈴木 忠樹, et al. エムポックスの検査体制の全国展開. 病原微生物検出情報月報. 2023. 44. 6. 91-92
ｍore...
MISC (86)：
  • Sho Miyamoto, Yudai Kuroda, Takayuki Kanno, Akira Ueno, Nozomi Shiwa-Sudo, Naoko Iwata-Yoshikawa, Yusuke Sakai, Noriyo Nagata, Takeshi Arashiro, Akira Ainai, et al. Estimating serum cross-neutralizing responses to SARS-CoV-2 Omicron sub-lineages elicited by pre-Omicron or Omicron breakthrough infection with exposure interval compensation modeling. medRxiv. 2023
  • 坂井祐介, 永田典代, 岩田奈織子, 森川茂, 海老原秀喜, 鈴木忠樹. Histopathological analysis on pathological change of splenic B cells in Cynomolgus monkey infected with Reston Ebolavirus. 日本ウイルス学会学術集会プログラム・予稿集(Web). 2023. 70th
  • 北村秀智, 北村秀智, 倉崎晴彰, 倉崎晴彰, 大内政輝, 長友一剛, 大橋啓史, 岩田(吉河)奈織子, 志和(須藤)希, 坂井祐介, et al. Preclinical and clinical characterization of PA-001, a macrocyclic peptide that targets the S2 subunit of SARS-CoV-2 spike protein. 日本ウイルス学会学術集会プログラム・予稿集(Web). 2023. 70th
  • 宮崎かや, 宮崎かや, 志和(須藤)希, 岩田(吉河)奈織子, 坂井祐介, 鈴木忠樹, 長谷川秀樹, 長谷川秀樹, 永田典代. Pathological study of the infection and long-term clinical condition of a rat model using SARS-CoV-2 mouse passaged virus. 日本ウイルス学会学術集会プログラム・予稿集(Web). 2023. 70th
  • 河村達郎, 河村達郎, 大内政輝, 長澤孝行, 大橋啓史, 岩田(吉河)奈織子, 志和(須藤)希, 坂井祐介, 松井克磨, 松本正俊, et al. Identification and in vivo therapeutic efficacy of PA-001, a macrocyclic peptide that targets the S2 subunit of SARS-CoV-2 spike protein. 日本ウイルス学会学術集会プログラム・予稿集(Web). 2023. 70th
ｍore...
Patents (1)：
Education (1)：
  • 1988 - 1994 日本獣医畜産大学 獣医畜産学部 獣医学科
Professional career (1)：
  • 博士(医学) (東京大学)
Association Membership(s) (4)：
THE JAPANESE SOCIETY FOR VACCINOLOGY ,  THE JAPANESE SOCIETY OF VETERINARY SCIENCE ,  THE JAPANESE SOCIETY OF PATHOLOGY ,  THE JAPANESE SOCIETY FOR VIROLOGY
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM